QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
NYSEAMERICAN:NAVB

Navidea Biopharmaceuticals - NAVB Stock Forecast, Price & News

$0.25
+0.01 (+4.21%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.24
$0.26
50-Day Range
N/A
52-Week Range
$0.20
$1.34
Volume
95,522 shs
Average Volume
171,820 shs
Market Capitalization
$7.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NAVB stock logo

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Stock

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NAVB Stock News Headlines

Navidea Biopharmaceuticals, Inc. (NAVB)
See More Headlines
Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NAVB Company Calendar

Last Earnings
11/10/2021
Today
11/30/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic Substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NYSEAMERICAN:NAVB
Previous Symbol
NYSEMKT:NAVB
CUSIP
63937X10
Employees
11
Year Founded
N/A

Profitability

Net Income
$-10,720,000.00
Net Margins
-1,557.43%
Pretax Margin
-1,555.14%

Debt

Sales & Book Value

Annual Sales
$920,000.00
Book Value
$0.46 per share

Miscellaneous

Free Float
20,407,000
Market Cap
$7.95 million
Optionable
Optionable
Beta
1.73

Key Executives

  • Ms. Erika L. Eves (Age 52)
    VP of Fin. & Admin.
    Comp: $213.25k
  • Dr. Michael Stanley Rosol Ph.D. (Age 54)
    Sr. VP & Chief Medical Officer
    Comp: $336.31k
  • Mr. Jeffrey G. Smith
    VP of Operations













NAVB Stock - Frequently Asked Questions

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a decrease in short interest in October. As of October 31st, there was short interest totaling 114,400 shares, a decrease of 50.2% from the October 15th total of 229,900 shares. Based on an average daily volume of 157,400 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.5% of the shares of the company are sold short.
View Navidea Biopharmaceuticals' Short Interest
.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) announced its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. The biopharmaceutical company earned $0.10 million during the quarter, compared to analyst estimates of $0.60 million. Navidea Biopharmaceuticals had a negative net margin of 1,557.43% and a negative trailing twelve-month return on equity of 116.36%.

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

Who are Navidea Biopharmaceuticals' major shareholders?

Navidea Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%). Insiders that own company stock include Jed Latkin, John K Jr Scott and Malcolm G Witter.
View institutional ownership trends
.

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $0.25.

How much money does Navidea Biopharmaceuticals make?

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) has a market capitalization of $7.93 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-10,720,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The official website for the company is www.navidea.com. The biopharmaceutical company can be reached via phone at (614) 793-7500, via email at ir@navidea.com, or via fax at 614-793-7522.

This page (NYSEAMERICAN:NAVB) was last updated on 11/30/2022 by MarketBeat.com Staff